This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Top Trial Firm, Cohen, Placitella & Roth, PC, Investigating Atossa Genetics, Inc, For FDA Warning Letter And Product Recall

Stocks in this article: ATOS

PHILADELPHIA, Oct. 23, 2013 /PRNewswire/ -- Cohen, Placitella and Roth, PC is investigating claims on behalf of investors who purchased Atossa Genetics, Inc. ("Atossa" or the "Company") (Nasdaq: ATOS) stock between November 8, 2012 and October 4, 2013, inclusive. The investigation concerns whether Atossa and certain of its officers and/or directors disseminated material false and misleading information to investors in violation of Sections 10(b), and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder, and Sections 11, 12(a)(2) and 15 of the Securities Act of 1933.

Atossa is a healthcare company focused on the commercialization of cellular and molecular diagnostic risk assessment products for the detection of pre-cancerous conditions that could lead to breast cancer. On November 9, 2012, Atossa filed its Prospectus for its initial public offering ("IPO"), which forms part of the Registration Statement that became effective on November 8, 2012.  Pursuant to the IPO, Atossa sold 800,000 shares at $5.00 per share, garnering proceeds of $3,720,000 to the Company.  The Prospectus stated that Atossa's medical devices were "cleared" by the U.S. Food and Drug Organization for, "collect[ing] fluid samples from the breast milk ducts, where, according to the National Cancer Institute, over 95% of breast cancers arise." On February 20, 2013, in a warning letter, the FDA raised concerns about procedures leading to design changes to Atossa's MASCT [Mammary Aspiration Specimen Cytology Test] System and potentially significant safety and effectiveness issues related to those changes.  The FDA also noted Atossa's failure to apply and receive marketing clearance for the design change to MASCT, a violation of U.S. law.  On Friday, October 4, 2013, Atossa began voluntarily recalling from the market the ForeCYTE BreastHealth Test and the MASCT device. This voluntary recall includes the MASCT System Kit and Patient Sample Kit. In Atossa's Form 8-K  filed on October 4, 2013, the Company stated: "The vast majority of these [recalled] products (approximately ninety percent) are in inventory with Atossa's distributors and the remaining quantities are at customer sites across the United States." On this news, shares of Atossa fell $2.50 per share to $2.82, a loss of almost 47% on intraday trading on October 7, 2013.

If you have any information on Atossa's medical devices, or you wish to discuss what rights you may have related to a loss in your investment in Atossa, please contact Eduardo Texidor Jr. at or, toll free, at 1-888-375-7600. For those investors inquiring via email, please be sure to include "Atossa" in the subject line, the number of shares purchased, and your mailing address and telephone number.

Since 1973, Cohen, Placitella & Roth, PC has been recognized as one of the premier trial law firms in the country. The firm has extensive experience in prosecuting securities litigation involving violations of the federal securities laws, state law derivative actions and mergers and acquisitions cases, representing institutional investors such as public pension plans and union pension funds as well as individual shareholders suffering substantial investment losses due to corporate misconduct. LexisNexis Martindale-Hubbell® annually reports Cohen, Placitella & Roth's peer rating-the highest AV® - "a testament to professional excellence." Since the inauguration of its "Best Law Firms"' edition in 2010, U.S. News and World Report has annually listed Cohen, Placitella & Roth's as one of the top-tier class action law firms in the country.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs